1 |
Carreiras MC, Marco JL, "Recent approaches to novel anti-Alzheimer therapy", Curr Pharm Des., 10(25), pp.3167-3175, 2004.
DOI
|
2 |
Collins S, Sigtermans MJ, Dahan A, Zuurmond WW, Perez RS., "NMDA receptor antagonists for the treatment of neuropathic pain", Pain Med. 11(11), pp.1726-1742, 2010.
DOI
|
3 |
Alan H Nagahara1, David A Merrill1 et al., "Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease" Nature Medicine 15, pp.331-337, 2009.
DOI
|
4 |
A. Rocchi, S. Pellegrini, G. Siciliano and L. Murri, "Causative and susceptibility genes for Alzheimer's disease: a review", Brain Res. Bull., 61(1), pp.1-24, 2003.
DOI
|
5 |
Kerchner GA, Boxer AL., "Bapineuzumab", Expert Opin Biol Ther. 10(7), pp.1121-1130, 2010.
DOI
|
6 |
L. Aron and R. Klein, "Repairing the parkinsonian brain with neurotrophic factors", Trends Neurosci. 34(2), pp.88-100, 2011.
DOI
|
7 |
L. Y. Fan and M. J. Chiu, "Pharmacological treatment for Alzheimer's disease: current approaches and future strategies", Acta Neurol Taiwan. 19(4), pp.228-245, 2010.
|
8 |
Simmons DA, Rex CS, Palmer L, Pandyarajan V, Fedulov V, Gall CM, Lynch G., "Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice", Proc Natl Acad Sci USA. 24;106(12), pp.4906-4911, 2009.
DOI
|
9 |
Lim ST, Airavaara M, Harvey BK., "Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS", Pharmacol Res. 61(1), pp.14-26, 2010.
DOI
|
10 |
Wu YP, Chen WS, Teng C, Zhang N., "Stem cells for the treatment of neurodegenerative diseases", Molecules 15; pp.6743-6758, 2010.
DOI
|
11 |
Z. Griliches, Patent statistics as economic indicators: A survey, Journal of economic literature, 18, pp.1661-1707, 1990.
|
12 |
S. K. Sonkusare et al., "Dementia of Alzheimer's disease and other neurodegenerative disorders-memantine, a new hope", Pharmacological Research, 51(1), pp.1-17, 2005.
DOI
|
13 |
P. Stanzione and D. Tropepi. "Drugs and clinical trials in neurodegenerative diseases", Ann Ist Super Sanita, 47(1), pp.49-54, 2011.
|
14 |
Alan L. Porter and Scott W. Tech Mining: Exploiting New Technologies for Competitive Advantage, Cunningham, Hoboken, NJ, John Wiley & Sons, 33-40. 2005.
|
15 |
Halperin I, Morelli M, Korczyn AD, Youdim MB, Mandel SA., "Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases", Neurotherapeutics. 6(1), pp.128-140, 2009.
DOI
|
16 |
J.B. Standridge, "Pharmacotherapeutic approaches to the treatment of Alzheimer's disease", Clin. Ther., 26(5), pp.615-630, 2004.
DOI
|